157 related articles for article (PubMed ID: 4042084)
1. Response surface methodology and the design of clinical trials for the evaluation of cancer chemotherapy.
Carter WH
Cancer Treat Rep; 1985 Oct; 69(10):1049-53. PubMed ID: 4042084
[No Abstract] [Full Text] [Related]
2. Factorial designs for randomized clinical trials.
Byar DP; Piantadosi S
Cancer Treat Rep; 1985 Oct; 69(10):1055-63. PubMed ID: 4042085
[No Abstract] [Full Text] [Related]
3. Review of the application of response surface methodology in the combination therapy of cancer.
Carter WH; Wampler GL
Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113
[No Abstract] [Full Text] [Related]
4. Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials.
Mietlowski W; Wang J
Contemp Clin Trials; 2007 Sep; 28(5):674. PubMed ID: 17449334
[No Abstract] [Full Text] [Related]
5. An efficient design for phase III studies of combination chemotherapies.
Ellenberg SS; Eisenberger MA
Cancer Treat Rep; 1985 Oct; 69(10):1147-54. PubMed ID: 4042093
[No Abstract] [Full Text] [Related]
6. Chemotherapy for adult soft tissue sarcoma. Does it work?
Saeter G
Acta Orthop Scand Suppl; 1997 Feb; 273():139-44. PubMed ID: 9057605
[No Abstract] [Full Text] [Related]
7. Influence of measurement error on response rates.
Warr D; McKinney S; Tannock I
Cancer Treat Rep; 1985 Oct; 69(10):1127-32. PubMed ID: 4042092
[No Abstract] [Full Text] [Related]
8. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
9. Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach.
Emerson SS
Biometrics; 1995 Sep; 51(3):1152-62. PubMed ID: 7548699
[TBL] [Abstract][Full Text] [Related]
10. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
Tamura K
Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
[No Abstract] [Full Text] [Related]
11. Is response rate relevant to the phase II trial design of targeted agents?
Dowlati A; Fu P
J Clin Oncol; 2008 Mar; 26(8):1204-5. PubMed ID: 18285601
[No Abstract] [Full Text] [Related]
12. [Why is it sometimes necessary to include a large number of patients in clinical trials?].
Hill C
Bull Cancer; 1989; 76(6):569-71. PubMed ID: 2570613
[No Abstract] [Full Text] [Related]
13. Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.
Markman M
Cancer; 2010 Nov; 116(22):5116-8. PubMed ID: 20665504
[No Abstract] [Full Text] [Related]
14. [Current status and issues in clinical trials of anticancer agents].
Kojima H
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
[TBL] [Abstract][Full Text] [Related]
15. Second-line chemotherapy in head and neck cancer: what should we expect?
Büntzel J; Micke O
Expert Rev Anticancer Ther; 2009 Mar; 9(3):269-73. PubMed ID: 19275504
[No Abstract] [Full Text] [Related]
16. Re: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?
Bhutani M; Pathak AK
J Natl Cancer Inst; 2008 Sep; 100(18):1334; author reply 1334-5. PubMed ID: 18780866
[No Abstract] [Full Text] [Related]
17. Discrete event simulation applied to pediatric phase I oncology designs.
Barrett J; Skolnik J; Jayaraman B; Patel D; Adamson P
Clin Pharmacol Ther; 2008 Dec; 84(6):729-33. PubMed ID: 18923388
[No Abstract] [Full Text] [Related]
18. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Nagourney RA
Gynecol Oncol; 2000 Jan; 76(1):143. PubMed ID: 10620464
[No Abstract] [Full Text] [Related]
19. Modelling chemotherapy resistance in palliation and failed cure.
Monro HC; Gaffney EA
J Theor Biol; 2009 Mar; 257(2):292-302. PubMed ID: 19135065
[TBL] [Abstract][Full Text] [Related]
20. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
